Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03449147
Recruitment Status : Active, not recruiting
First Posted : February 28, 2018
Last Update Posted : August 12, 2019
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
The primary objective of this study will be to evaluate the efficacy of gefapixant (MK-7264) in reducing cough frequency as measured over a 24-hour period. It is hypothesized that at least one dose of gefapixant is superior to placebo in reducing coughs per hour (over 24 hours) at Week 24.

Condition or disease Intervention/treatment Phase
Chronic Cough Drug: Gefapixant 45 mg BID Drug: Gefapixant 15 mg BID Drug: Placebo Phase 3

Detailed Description:
This study will have a main 24-week treatment period and a 28-week extension period of treatment. Participants at selected sites and countries who complete the main and extension study periods may consent to participate in an observational, 3-month, Off-treatment Durability Study Period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1290 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants with refractory or unexplained chronic cough will be randomized to 1 of 3 treatment groups: gefapixant 45 mg twice daily (BID), gefapixant 15 mg BID, or placebo.
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants With Chronic Cough (PN030)
Actual Study Start Date : March 15, 2018
Estimated Primary Completion Date : January 8, 2021
Estimated Study Completion Date : January 8, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cough

Arm Intervention/treatment
Experimental: Gefapixant 45 mg BID
Participants will receive a gefapixant 45 mg tablet BID during the main study period (24 weeks) and also during the extension period (28 weeks).
Drug: Gefapixant 45 mg BID
Gefapixant 45 mg tablet to be administered orally BID
Other Name: MK-7264

Experimental: Gefapixant 15 mg BID
Participants will receive a gefapixant 15 mg tablet BID during the main study period (24 weeks) and also during the extension period (28 weeks).
Drug: Gefapixant 15 mg BID
Gefapixant 15 mg tablet to be administered orally BID
Other Name: MK-7264

Placebo Comparator: Placebo
Participants will receive a matching placebo tablet BID during the 24-week main study period and during the 28-week extension period.
Drug: Placebo
Placebo tablet administered orally BID




Primary Outcome Measures :
  1. 24-hour Coughs per Hour at Week 24 [ Time Frame: Week 24 ]
    Assessment of 24-hour coughs per hour (average hourly cough frequency based on 24-hour sound recordings), to be evaluated using a digital recording device which records sounds from the lungs and trachea through a chest contact sensor, as well as ambient sounds through a lapel microphone.

  2. Percentage of Participants Experiencing At Least One Adverse Event (AE) During Treatment and Follow-up [ Time Frame: Up to 54 weeks ]
    Assessment of participants who have at least one AE during the main study period (24 weeks), the treatment extension period (28 weeks), and during 2 weeks of follow-up by telephone.

  3. Percentage of Participants Who Have a Study Drug Discontinued Due to an AE [ Time Frame: Up 52 weeks ]
    Assessment of participants who stop study treatment due to an AE during the main study period (24 weeks) or the treatment extension period (28 weeks).


Secondary Outcome Measures :
  1. Change From Baseline of Awake Coughs Per Hour at Week 24 [ Time Frame: Baseline, Week 24 ]
    To evaluate the efficacy of gefapixant by assessment of coughs per hour while the participant is awake, evaluated using a chest contact sensor to record sounds from the lungs and trachea and a lapel microphone to record ambient sounds.

  2. Percentage of Participants With a ≥1.3-point Increase From Baseline in the Leicester Questionnaire (LCQ) Total Score at Week 24 [ Time Frame: Baseline, Week 24 ]
    To evaluate the ability of gefapixant to provide a clinically significant improvement in cough-specific health related quality of life (HRQoL), as indicated by a ≥1.3-point increase from Baseline in the LCQ total score at Week 24. The 19-item LCQ assesses the impact of cough severity in three HRQoL domains (physical, social and psychological). The LCQ is calculated as a mean score for each domain ranging from 1 to 7, with a total score ranging from 3 to 21.

  3. Percentage of Participants With a ≥30% Reduction From Baseline in 24-hour Coughs Per Hour at Week 24 [ Time Frame: Baseline, Week 24 ]
    To evaluate the efficacy of gefapixant based on clinically meaningful (≥30%) reduction from Baseline in 24-hour coughs per hour at Week 24. Coughs per hour are evaluated using a chest contact sensor to record sounds from the lungs and trachea and a lapel microphone to record ambient sounds.

  4. Percentage of Participants with ≥1.3-point Reduction From Baseline of Mean Weekly Cough Severity Diary (CSD) Total Score at Week 24 [ Time Frame: Baseline, Week 24 ]
    To evaluate the efficacy of gefapixant based on the percentage of participants with ≥1.3-point reduction of the mean weekly CSD total score at Week 24. Participants will record their cough frequency, intensity, and disruption due to cough using the 7-item CSD. Participants will rate each item using an 11-point scale ranging from 0 to 10 with higher scores indicating greater severity.

  5. Percentage of Participants with ≥2.7-point Reduction From Baseline of Mean Weekly CSD Total Score at Week 24 [ Time Frame: Baseline, Week 24 ]
    To evaluate the efficacy of gefapixant based on the percentage of participants with ≥2.7-point reduction of the mean weekly CSD total score at Week 24. Participants will record their cough frequency, intensity, and disruption due to cough using the 7-item CSD. Participants will rate each item using an 11-point scale ranging from 0 to 10 with higher scores indicating greater severity.

  6. Percentage of Participants With a ≥30 mm Reduction From Baseline in Cough Severity Visual Analog Scale (VAS) Score at Week 24 [ Time Frame: Baseline, Week 24 ]
    To evaluate the efficacy of gefapixant based on improvement from Baseline in cough severity, assessed by the proportion of participants with a ≥30 mm reduction from baseline in Cough Severity VAS score at Week 24. The VAS is a single-item questionnaire with the response on a 100- point scale ranging from 0 ("No Cough") to 100 ("Extremely Severe Cough").



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Chest radiograph or computed tomography scan of the thorax (within 5 years of Screening/Visit 1 and after the onset of chronic cough) not demonstrating any abnormality considered to be significantly contributing to the chronic cough or any other clinically significant lung disease in the opinion of the principal investigator or the sub-investigator
  • Has had chronic cough for at least 1 year with a diagnosis of refractory chronic cough or unexplained chronic cough
  • Is a female who is not pregnant, not breastfeeding, not of childbearing potential, or agrees to follow contraceptive guidance
  • Provides written informed consent and is willing and able to comply with the study protocol (including use of the digital cough recording device and completion of study questionnaires)

Exclusion Criteria:

  • Is a current smoker or has given up smoking within 12 months of Screening, or is a former smoker with greater than 20 pack-years
  • Has a history of respiratory tract infection or recent clinically significant change in pulmonary status
  • Has a history of chronic bronchitis
  • Is currently taking an angiotensin converting enzyme inhibitor (ACEI), or has used an ACEI within 3 months of Screening
  • Has an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m^2 at Screening OR an eGFR ≥30 mL/min/1.73 m^2 and <50 mL/min/1.73 m^2 at Screening with unstable renal function
  • Has a history of malignancy <=5 years
  • Is a user of recreational or illicit drugs or has had a recent history of drug or alcohol abuse or dependence
  • Has a history of anaphylaxis or cutaneous adverse drug reaction (with or without systemic symptoms) to sulfonamide antibiotics or other sulfonamide-containing drugs
  • Has a known allergy/sensitivity or contraindication to gefapixant
  • Has donated or lost >=1 unit of blood within 8 weeks prior to the first dose of gefapixant
  • Has previously received gefapixant or is currently participating in or has participated in an interventional clinical study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03449147


  Show 171 Study Locations
Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Study Director: Medical Director Merck Sharp & Dohme Corp.

Layout table for additonal information
Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT03449147     History of Changes
Other Study ID Numbers: 7264-030
MK-7264-030-02 ( Other Identifier: Merck Protocol Number )
2017-003559-49 ( EudraCT Number )
First Posted: February 28, 2018    Key Record Dates
Last Update Posted: August 12, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
URL: http://engagezone.msd.com/ds_documentation.php

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cough
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms